RADIOPHARMACEUTICAL PREPARATIONS USE

Brand Owner (click to sort) Address Description
CURIUM CURIUM NETHERLANDS B.V. WESTERDUINWEG 3 PETTEN 1755LE Netherlands Radiopharmaceutical preparations for use in nuclear medicine; Pharmaceutical kits for making radiopharmaceutical preparations;Medical generators for use in the production and transportation of nuclear medicine and component parts therefor; Radioaerosol generators, namely, nebulizers for administering radioactive medicine and imaging solutions in gaseous form for medical imaging procedures and component parts therefor; Elution shields, namely, nuclear medicine radiation apparatus for collection of sodium-pertechnetate from Mo99/ Tc99m generators and radiation shielding;
GEGANT ITM Medical Isotopes GmbH Lichtenbergstr. 1 85748 Garching Germany Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing Gallium-68 for treating and diagnosing tumours; anti-cancer preparations, namely, Gallium-68 compounds, including 68-Ga chlorides; anti-cancer preparations, namely, Gallium-68 for use in the field of targeted radionuclide therapy of cancers, in particular prostate cancer and neuroendocrine tumours; cancer diagnostic preparations for medical purposes, namely, Gallium-68 compounds, including 68-Ga peptide chelates, in particular 68-Ga-Dotatoc and 68-Ga-Dotatate, 68-Ga salts, in particular 68-Ga chlorides; Gallium-68 for use as radiotracers in pet scans or combined PET/CT scans;Pharmaceutical advice in relation to radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, advice in relation to radiopharmaceuticals for the therapy and diagnosis of diseases, in particular tumour diseases, namely, pharmaceutical advice in relation to radiopharmaceuticals coupled to somatostatin analogues and advice in relation to the manufacture of personalised radiopharmaceutical products containing 68-Ga for use in medicine;Medical apparatus and instruments for use in positron emission tomography (PET) imaging, namely, Ge-68/Ga-68 radionuclide generators for pharmaceutical purposes as source of radionuclides being positron emitters in the field of Positron Emission Tomography - Computed Tomography (PET/CT);Scientific and technological services and research on radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, services relating to radiopharmaceuticals for the therapy and diagnosis of diseases and services relating to radiopharmaceuticals coupled to somatostatin analogues for the diagnosis and treatment of tumours, namely, scientific and product research and development;
GEGANT ITG Isotope Technologies Garching GmbH Lichtenbergstr. 1 85748 Garching Germany Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing Gallium-68 for treating and diagnosing tumours; anti-cancer preparations, namely, Gallium-68 compounds, including 68-Ga chlorides; anti-cancer preparations, namely, Gallium-68 for use in the field of targeted radionuclide therapy of cancers, in particular prostate cancer and neuroendocrine tumours; cancer diagnostic preparations for medical purposes, namely, Gallium-68 compounds, including 68-Ga peptide chelates, in particular 68-Ga-Dotatoc and 68-Ga-Dotatate, 68-Ga salts, in particular 68-Ga chlorides; Gallium-68 for use as radiotracers in pet scans or combined PET/CT scans;Pharmaceutical advice in relation to radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, advice in relation to radiopharmaceuticals for the therapy and diagnosis of diseases, in particular tumour diseases, namely, pharmaceutical advice in relation to radiopharmaceuticals coupled to somatostatin analogues and advice in relation to the manufacture of personalised radiopharmaceutical products containing 68-Ga for use in medicine;Medical apparatus and instruments for use in positron emission tomography (PET) imaging, namely, Ge-68/Ga-68 radionuclide generators for pharmaceutical purposes as source of radionuclides being positron emitters in the field of Positron Emission Tomography - Computed Tomography (PET/CT);Scientific and technological services and research on radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, services relating to radiopharmaceuticals for the therapy and diagnosis of diseases and services relating to radiopharmaceuticals coupled to somatostatin analogues for the diagnosis and treatment of tumours, namely, scientific and product research and development;
NEOPROBE NEOPROBE CORPORATION 425 Metro Place North Suite 300 Columbus OH 430171367 radiopharmaceutical preparations for use in detecting neoplastic tissue;radiation detecting probe for medical use; microprocessor based controller and analyzer for medical diagnostic use;
ONCOSTRON BIO-NUCLEONICS, INC. 10425 NW 37th Terrace Doral FL 33178 RADIOPHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF CANCER;
PROGNOX AMERSHAM INTERNATIONAL PLC AMERSHAM PLACE LITTLE CHALFONT, BUCHINGHAMSHIRE radiopharmaceutical preparations for use in medical diagnosis and imaging;PROGNOSTIC;
RIGSYSTEM NEOPROBE CORPORATION 425 Metro Place North Suite 300 Columbus OH 430171367 radiopharmaceutical preparations for use in detecting neoplastic tissue;RIG SYSTEM;radiation detecting probe and microprocessor-based controller and analyzer, all for medical diagnostic use;
SOLUCIN ITM Isotope Technologies Munich SE LICHTENBERGSTRASSE 1 GARCHING 85748 Germany Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing lutetium for treating and diagnosing tumours;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal when the potential of explosive liquid oxygen is eliminated. The radioactive diagnostic radiopharmaceutical requires no further cold or refrigerated storage, including with respect to shipping, subsequent to stabilization. The preferred composition can be reconstituted "on site" by the addition of a suitable diluent to bring the radiopharmaceutical complex into solution at a desired concentration.